Aurinia Pharmaceuticals Inc.
- AUPH
- NASDAQ
- Biotechnology
- Autoimmune Disease Therapies
- Lupus Nephritis Treatment
$16.51
Today −1.31%Quote Oct 16, 2026, 08:00 PM UTC
−2.65%over the last month
Max drawdown −7.5%From 1-month high −2.7%3 months +8.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$2.20B
Quote Oct 16
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$16.00
−3.1% from here
Floor
$16.36
0.9% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AUPHPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $83.2M
- Product$79.4M95.4%
- License, Collaboration and Royalty Revenue$3.8M4.6%
Industry
Biotechnology
Employees
128